DAIICHI SANKYO, INC.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Phase 3
Not yet recruiting
- Conditions
- Endometrial Cancer
- Interventions
- Drug: Chemotherapy
- First Posted Date
- 2025-06-15
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 710
- Registration Number
- NCT07022483
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Recurrent or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 76
- Registration Number
- NCT07015697
Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i
Active, not recruiting
- Conditions
- Advanced/Metastatic HER2-negative Breast Cancer
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 2200
- Registration Number
- NCT06975371
- Locations
- 🇺🇸
Flatiron Health, Inc, New York, New York, United States
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Phase 3
Not yet recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 686
- Registration Number
- NCT06899126
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
Recruiting
- Conditions
- HER2-positive Gastric CancerHER2-positive Gastroesophageal Junction
- Interventions
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 260
- Registration Number
- NCT06846996
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, China
🇨🇳Beijing GoBroad Hospital, Beijing, China
🇨🇳The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan
Recruiting
- Conditions
- HER2-positive Breast Cancer
- First Posted Date
- 2025-02-18
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 220
- Registration Number
- NCT06833268
- Locations
- 🇺🇸
Flatiron Health, Inc, New York, New York, United States
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Phase 2
Not yet recruiting
- Conditions
- Acute Myeloid LeukemiaLeukemia
- Interventions
- Drug: Quizartinib High DoseDrug: Quizartinib Low Dose
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 130
- Registration Number
- NCT06824168
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Weill Cornell, New York, New York, United States
🇰🇷National Cancer Center, Goyang-si, Korea, Republic of
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- First Posted Date
- 2025-02-11
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 582
- Registration Number
- NCT06819007
- Locations
- 🇺🇸
Miami Valley Hospital South, Centerville, Ohio, United States
🇨🇳Fudan University Shanghai Cancer Center, Shanghai Shi, China
🇯🇵National Cancer Center Hospital, Chuo-Ku, Japan
A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)
Recruiting
- Conditions
- Diabetic Peripheral Neuropathic Pain
- First Posted Date
- 2025-02-06
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 720
- Registration Number
- NCT06812117
- Locations
- 🇨🇳
China-Japan friendship hospital, Beijing, China
🇨🇳Xuanwu Hospital Capital Medical University, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 150
- Registration Number
- NCT06809764
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
🇨🇳Peking University International Hospital, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, China